Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlene Flournoy

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthCarolyn W Zhu, Charlene Flournoy, Rema Raman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2025
Employment, volunteering, and health-related resource use in pre-symptomatic AD: Results from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) studyCarolyn W Zhu, Charlene Flournoy, Rema Raman, et al.
Annals of Neurology|October 13, 2023
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer DiseaseJoshua D Grill, Charlene Flournoy, Shobha Dhadda, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2025
Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trialJoshua D Grill, Rema Raman, Charlene Flournoy, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthCarolyn W Zhu, Charlene Flournoy, Rema Raman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2025
Employment, volunteering, and health-related resource use in pre-symptomatic AD: Results from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) studyCarolyn W Zhu, Charlene Flournoy, Rema Raman, et al.
Annals of Neurology|October 13, 2023
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer DiseaseJoshua D Grill, Charlene Flournoy, Shobha Dhadda, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2025
Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trialJoshua D Grill, Rema Raman, Charlene Flournoy, et al.
Pageof 1